RUNX2 Antibodies

Santa Cruz Biotechnology features a diverse variety of RUNX2 monoclonal antibodies for investigating RUNX2 in various biological processes. RUNX2 monoclonal antibodies are validated for multiple applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). RUNX2, also known as Runt-related transcription factor 2, is a critical regulator of bone development and plays a vital role in osteoblast differentiation and skeletal morphogenesis. RUNX2 functions extend to various physiological processes, including the regulation of genes involved in bone formation and mineralization. Dysregulation of RUNX2 has been implicated in several bone-related diseases, making it a significant target for research in osteogenesis and related disorders. RUNX2 research has revealed its crucial role in bone metabolism and development. Understanding RUNX2 expression patterns and interactions provides valuable insights into skeletal disorders and potential therapeutic approaches. RUNX2 investigation continues to expand our knowledge of bone biology and pathology. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of RUNX2 and its impact on human health.